We assessed the changes in short-and long-term outcomes and their relation to implementation of new evidencebased treatments in all patients with non-ST-elevation myocardial infarction (NSTEMI) in Sweden over 20 years. 
Introduction
During the last 25 years, the diagnosis and treatment of patients with unstable coronary artery disease, or later defined as non-STelevation acute coronary syndrome, has undergone dramatic changes. In the 1990s, the condition was identified mainly based on symptoms of chest pain and signs of ischaemia in electrocardiogram (ECG) at rest. 1 The definition has gradually changed to be based mainly on a transient elevation of cardio-specific troponins fulfilling the current definition of non-ST-elevation myocardial infarction (NSTEMI). 2 During the same time period the results of new clinical trials have supported the transition from treatments aiming mainly for relief of the ischaemic symptoms, e.g. nitroglycerine and betablockade, to being focused on elimination of the underlying atherothrombotic stenotic lesions by early revascularization, 3, 4 thrombin inhibition before and during the invasive procedures [5] [6] [7] [8] and long-term antiplatelet treatment with aspirin 9,10 and P2Y12-inhibitors. 11, 12 The evidence on the beneficial effects of individual treatments in clinical trials in NSTEMI have led to stepwise changes of the treatment strategies in the treatment guidelines 1, [13] [14] [15] [16] [17] [18] [19] and in real life. Although the efficacy of each new treatment modalities is evidence-based in clinical trials, the overall effectiveness of the accumulated 20 years of changes in treatment strategies in NSTEMI has not been comprehensively evaluated. Such an evaluation can only be performed based on detailed serial observations of patients, treatments and outcomes in real-life health care of all patients from a large stable population. As the analyses by necessity will be observational they need to consider not only the variable implementation of cardiovascular treatments over time in different parts of the health care system but also to compensate for gradual changes in background characteristics and comorbidities and also the time-related changes in mortality in the background population. The aims of this study were to describe the gradual implementation of new evidence-based treatments and the time-related changes in cardiovascular outcomes and to assess the associations between the implementation of new treatment strategies and the changes in short-and long-term outcomes, i.e. mortality, myocardial infarction (MI), heart failure, and stroke in patients with NSTEMI in the health care system of an entire country over 20 years.
Methods

Study population
All cases admitted to a coronary care unit or other specialized facility with a suspected or definite acute coronary syndrome are continuously included in the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry. 20 Currently, all Swedish hospitals (n = 72) that provide care for acute cardiac diseases participate.
This study included all cases in the SWEDEHEART registry admitted to a hospital with a NSTEMI between 1 January 1995 and 10 October 2014. All patients with a MI diagnosis were classified into either STelevation MI based on their ECG finding, or into NSTEMI. A report about time-trends for ST-elevation MI patients has previously been published. 21 During the years 1995-2001, the criteria for the diagnosis of acute MI were based on the World Health Organization criteria from 1994 22 combining symptoms, ECG changes, or both with the increase of an biochemical marker [mainly creatine kinase (CK)-MB] exceeding double the upper reference level as the biochemical criterion. From late 2001, the criteria for the diagnosis of MI were adopted and later continuously updated according to the European Society of Cardiology/American College of Cardiologists/American Heart Association consensus document, using troponin T or troponin I levels exceeding the 99th percentile in a healthy population together with either typical symptoms or ECG changes. [23] [24] [25] The high-sensitive troponins were introduced from 2011.
The changes in the use of biomarkers across the years is shown in Table 1 .
Baseline information on previously diagnosed concomitant diseases was enriched with information from the National Patient Registry, which includes the diagnoses of all hospital admissions in Sweden since 1987. Data regarding medication on admission, in-hospital treatments, and discharge medications are collected in the SWEDEHEART registry. The National Board of Health and Welfare approved merging of these registries. The regional ethics committee in Stockholm approved the study (dnr 2011/60-31/2).
Outcome definitions: re-infarction, stroke, heart failure, and mortality
The main outcomes were all-cause mortality, cardiovascular mortality, MI, hospitalization for heart failure, and stroke (see Supplementary material online, Table S1 ). For MI, stroke, and heart failure the latest available follow-up was on the 31 December 2013. Vital status was obtained from the Swedish Population register (last follow-up 11 November 2014, no loss to follow-up). Only patients with complete 1-year follow-up in 2013 were included in the 1-year mortality analyses.
Statistical analysis
The 20-year study period was divided into 2-year blocks and individuallevel data was used in the analysis. In the analysis, each patient was allowed to have only one NSTEMI during each 2-year block to allow the estimation of complications such as re-infarction, stroke, and heart failure hospitalization. However, the same individual could have a new NSTEMI in a different 2-year block. Since a patient could be analysed several times, we considered NSTEMI 'cases', and not 'patients'. The rationale for using 2-year blocks was the need for adequate numbers of all types of events in-hospital and at 1 year in order to provide adequate precision and narrow confidence intervals (CIs) when comparing standardized incidence rates between time periods and allow adjustments for multiple baseline characteristics and treatments. Continuous variables are displayed as medians (interquartile range) and categorical variables as proportions. Differences over time were tested by Jonckheere-Terpstra trend test for categorical variables and with linear-by-linear trend test for continuous data. Time-to-event was graphically displayed as Kaplan-Meier curves.
Standardization was performed using logistic regression models to account for the effect of differences in patient characteristics and treatments throughout the observation period. In short, stepwise adjustment for explanatory variables included (i) age (three knots, restricted cubic spline) and gender; (ii) baseline characteristics; and (iii) in-hospital coronary angiography (with/without revascularization) (see Supplementary material online, Table S2) .
To assess the effect of time on outcome, a similar analysis as for standardization was also performed with the simplifying assumption of a constant odds ratio (OR) for moving one 2-year time-block forward, facilitating the computation of CIs for the trend. A logistic regression model (for in-hospital) and a Cox-regression model (for 1-year event) was fitted. The outcome explored by this analysis was the composite of cardiovascular death or MI. Stepwise adjustments were performed as Relations between implementation of new treatments and improved outcomes in patients with NSTEMI To measure the absolute risk difference in outcome in relation to time, a sensitivity analysis was performed by fitting a linear regression model with robust standard errors to estimate dichotomous outcomes. The last 2-year block (2013-14) was omitted in this analysis, because not all cases had a full 1-year follow-up.
In order to account for mortality changes in the underlying background population, standardized incidence ratios (SIR) were also calculated, using an age, gender, and calendar matched general population from Statistics Sweden (www.scb.se).
Missing data were handled using multiple imputations with the method of chained equations. 26 Five imputed data sets were generated. As predictors, all variables in the model and events were used. The variable with most missing values was statin at discharge, with 7.8% missing.
All analyses were performed with R (version 3.1.0). The packages coin (trend-tests), mice (imputation), and rms (spline).
Results
Changing clinical characteristics on admission
In total, there were 205 693 cases with a NSTEMI (see Supplementary material online, Figure S1 ) registered in the SWEDEHEART registry between 1995 and 2014. During this 20-year time period, there were minor changes in the median age (74 years, interquartile range 65-82), about two-thirds of cases were male (62.6%), the number of current smokers was comparable (19%). The proportion with diabetes mellitus, hypertension, and previous revascularization increased, whereas the proportion with previous heart failure decreased ( Table 1) .
Changes in in-hospital treatments and medication at discharge
Over the 20 years, there was an increase in the number of cases who underwent in-hospital coronary angiography (1.9-73.2%), percutaneous coronary intervention (PCI) (4.8-52.3%), and coronary artery bypass grafting (CABG) (1.7-5.8%), without a tendency to reach a plateau phase at the end of the period (Figure 1 , Supplementary material online, Table S2 ). Simultaneously, there was an increase in the use of aspirin (82.8-90.0%), dual antiplatelet medication (0-72.7%), statins (13.3-85.6%), beta-blockade (72.9-86.7%), and ACEi/ARB (36.8-75.5%). When the medication reached a use above 70%, there was a slower increase and accordingly a trend to a plateau ( Figure 1 , Supplementary material online, Table S2 ).
In-hospital outcomes over 20 years
There was a decrease in in-hospital all-cause mortality (from 12.4% to 3.7%), cardiovascular mortality (from 11.7% to 3.2%), and MI (from 2.7% to 0.6%) (Figure 2A , Supplementary material online, Table  S3 ). The reductions in event rates were continuous over time, except for in-hospital mortality where there was no further decrease during the last 6 years of follow-up. Concerning the composite of in-hospital . Figure 2B , Supplementary material online, Table S3 ).
The multivariable modelling of the effect of moving a 2-year time block forward on the composite outcome of in-hospital cardiovascular mortality/MI showed, after adjusting for age and gender, an OR of 0.81 (95% CI 0.81-0.82), which increased to OR 0.85 (95% CI 0.84-0.86) by adjustment for changes in baseline characteristics, and increased to a similar extent to OR 0.89 (95% CI 0.88-0.90) by adjustment for changes in invasive treatment. Thus, also in this model the changes in baseline characteristics and early invasive procedure did only partly explain the time related reduction in in-hospital event rates ( Figure 3) . This finding was supported by stepwise adjustments in linear regression models estimating the risk difference, while moving forward a 2-year block in time, showing that in-hospital procedures only partially explained improvements in in-hospital events (see Supplementary material online, Figure S3 ).
One-year outcomes over 20 years
Similarly, there was a substantial, consistent, and continuous decrease in all outcomes in the first year following the admission for NSTEMI for the entire 20-year period ( Figure 2C ). There was a decrease in allcause mortality (26.0-14.8%), cardiovascular mortality (23.1-10.4%), MI (15.2-9.9%), heart failure readmission (10.3-7.4%), and ischaemic stroke (4.1-2.9%). If patients who were admitted in 2011/12 by multivariable modelling had been admitted in 1997/98 and had the same age and gender distribution and the same baseline characteristics, their mortality/MI rate would have been 33 .4% instead of the observed 1-year event rate of 34.5%. If they also were modelled to receive the same invasive in-hospital treatments the mortality/MI rate would have been 25.0%. This is only slightly higher than the observed 1-year event rate in 2011/12 of 22.0% ( Figure 2D , Supplementary material online, Table S4) indicating that the reductions in mortality/MI rate over the years mainly were explained by the increase in invasive treatment.
The multivariable modelling of the effect of moving a 2-year time block forward on the composite 1-year outcome of cardiovascular mortality/MI among hospital survivors, showed after adjusting for age, gender, and baseline characteristics, an OR of 0.92 (95% CI 0.92-0.93), which was increased to OR 0.97 (95% CI 0.96-0.97) by adjusting for the rise in invasive treatment and to OR 0.99 (95% CI 0.98-0.99) by adjusting for changes in discharge medications. These findings support that the main benefit in 1-year outcomes was accomplished by changes in early invasive procedures but that also changes in discharge medications contributed to the improvements (Figure 3) . This finding was further supported by stepwise adjustments in linear regression models, which estimated the risk difference for moving forward a 2-year block. This sensitivity analyses showed both a decline in 1-year cardiovascular mortality/MI for hospital survivors after adjustments for in-hospital invasive procedures as well as for discharge medications (see Supplementary material online, Figure S3 ).
Development of mortality over 20 years
The 1-year mortality of the NSTEMI cases was also compared with an age-, gender-, and calendar-year matched Swedish background population ( Figure 2C , Supplementary material online, Table S5, Figure  S2 ). Compared with this population, the risk of death among NSTEMI patients was 5.5 80-3.19) ]. The long-term follow-up beyond one year showed that the reductions in mortality as well as MI, heart failure, and stroke were sustained over time with substantially lower long-term event rates for each more recent admission period (Figure 4) .
Discussion
This study is a unique presentation of the development of treatments and outcomes in all patients with NSTEMI in an entire country during 20 years. From 1995 to 2014, there was a gradual uptake of new evidence-based treatments. During the same time, in-hospital mortality was reduced to a quarter (to an absolute rate of 3.7%) whereas 1-year cardiovascular mortality was halved (to an absolute rate of 10.4%). In comparison to the background population, which had an unchanged mortality during this period, the risk of dying in the year following NSTEMI was reduced from 5 to 3 times higher than the general population average. The multivariable analyses suggested that the improvements in outcomes mainly were explained by the increasing implementation of an early invasive treatment strategy and most likely the associated use of dual antiplatelet treatment as the differences in 1-year cardiovascular mortality and MI rates were almost eliminated by adjustments for the changes of these new treatments. Finally, the study demonstrated that the benefits in 1-year outcomes persisted and were even further improved during the up to 20 years follow-up.
The association of the gradual uptake of new treatments and continued improvements in survival are consistent with a few other realworld registries with serial evaluation of large cohorts of patients with NSTEMI over more than 10 years. [27] [28] [29] [30] [31] [32] The results from these registries were obtained through snapshots of data during short time-intervals from certain (often research-oriented and not allcomers) centres or regions, and provided mainly short-term mortality outcomes. The French FAST-MI study used 1-month observation periods every fifth year to show a decreased 6-month mortality from 17.2% to 6.3% between 1995 and 2015, but with little change beyond the year 2010. 30 The continuous UK MINAP registry between 2003
and 2013 showed a reduced 6-month mortality from 10.8% to 7.6%. 28 Similarly, the Polish ACS-registry covering the years 2004 to 2010, showed a decreased 1-year mortality from 19.1% to 14.5%. 27 The improved 1-year survival over 20 years in the current SWEDEHEART registry concur with these data, even when including the total NSTEMI population from an entire nation with patients from a diversity of settings and backgrounds. In contrast to the FAST-MI study, 30 we could not observe any plateauing in mortality rates probably indicating that with a continued increase in uptake of recommended therapies there is room for further improvements in outcomes. In the current study, the continuous improval in 1-year survival in patients with NSTEMI was supported be the gradually decreasing difference in survival compared with the general population and as the improvement was sustained during longer term follow-up. The current study also showed that a significant reduction of the major non-fatal cardiovascular complications after NSTEMI, such as MI, heart failure, and stroke, which benefits also were sustained and further expanded during 20-years follow-up. These findings are in line with a previous study from the GRACE registry in 2007, corresponding to the first 10 years of this analysis, showing that temporal changes in treatment are not only associated with a decline in mortality, but also in heart failure and MI, as well as lower stroke events at 6 months. 29 Both at in-hospital and at 1-year follow-up, there was a less steep fall in new MIs, heart failure, and stroke events than in cardiovascular deaths. The reason for this difference is speculative, but for in-hospital events this difference might be explained by other events such as fatal arrhythmias or possible new fatal MI or cardiogenic shock, not fulfilling the definition for a new MI or heart failure event. In the long-term, other competing events may explain the lower rate of new cardiac re-admissions compared with cardiovascular deaths. Only re-admissions for heart failure, stroke, or a new MI event counts as a new event, whereas many patients might have died without having the disease, or without being diagnosed with a cardiac disease. Hence, there was a decline in all-cause mortality, which is mainly explained by the decline in cardiovascular death during the first year of follow-up. The decline in cardiovascular death seemed more pronounced at the end of the time-period. The main cause of the reduction in non-fatal as well as fatal event rates seemed to be the utilization of the new invasive and medical treatments. As there is still no plateauing of cardiovascular death, MI, heart failure, or stroke, continued implementation of the current treatment strategy could be expected to further benefit NSTEMI patients. Based on the multivariable modelling the magnitude of benefit by the change of therapeutic strategy from 1995 to 2014 could be estimated to be around 8% absolute reduction in the 1-year rate of death/MI, despite any other changes in the patient population. Therefore, the number needed to treat by the new compared with the old strategy would be 12 to save one event of death/MI. This change of treatment strategy should therefore be considered for all patients with NSTEMI. 33 This study found strong support for significant associations between the temporal changes in the invasive and medical treatment strategies and the improvement in outcomes during 20 years. However, the observational approach makes it very difficult to ascertain the specific contribution of each individual treatment modality on outcomes. It is also not possible to explore the difference in outcome between patients treated only medically or invasively. Only an adequately designed controlled trial with random treatment assignments could estimate the effect of a specific treatment and avoid the risk of selection bias inherent to observational and registry studies. The observational nature of the study also makes it difficult to prove causation between the changed use of specific therapies and the changes in outcomes. However, the current findings are in line with a study from MINAP registry, 28 which found that the utilization of an early invasive strategy (defined as the in-hospital use of coronary angiography, PCI, or CABG) explained 46.1% of the temporal improvements in mortality, whereas the increased use of pharmacotherapy explained less. However, the impact of medications at discharge could not be fully assessed in neither MINAP, nor in the current study, as the implementation of dual antiplatelet and anticoagulant treatment was closely connected to the implementation of the early invasive strategy. In the MINAP study, the use of statins, beta-blockers, ACEi/ARB, and aspirin was high (>80-90%) during the whole study period from 2003 to 2013, whereas P2Y 12 -inhibitor use was high at the end of the time-period. In the current study lasting from 1995-2014, there was a considerably larger change in the use of secondary preventive medication at discharge, including ACEi/ARB and statins, which might have contributed to a somewhat stronger association between the changes of medical treatment and outcomes in our study. This study has some limitations. First, the recommendations on diagnosing a MI have been continuously upgraded with improved methodology to detect myocardial injury. 2 Especially, the increasing use of high-sensitive troponins from 2011 ( Table 1 ) and onwards, an increasing number of smaller and possibly lower-risk MIs may have fulfilled the criteria for NSTEMI, which previously were classified as unstable angina. The inclusion of such potentially lower risk patients in the later cohorts might have led to an overestimation of the improvement in the observed outcomes. However, a real improvement in outcomes is likely to be present, as the decline in event rates continued beyond the first years of introducing high-sensitive troponins. Secondly, the definition of diseases recorded in the registry may have changed over time, e.g. hypertension was initially based only on ICD-codes, but in the later years also included the use of anti-hypertensive medications. Also, the definition of other co-morbidities in the community in the later years has changed, such as heart failure now also including patients with less severe heart failure forms, and chronic kidney disease being defined by estimated renal function measures. In this study, however, we could not account for these changes in definitions over time. Finally, this study does not account for the effects of changes in the methodology at invasive procedure or strategy, such as a switch from femoral to radial puncture site, use of newer catheters, and newer generation drug-eluting stents, nor does it account for the change in time delay from presentation to interventions, which all are associated with better outcomes in randomized clinical trials.
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Conclusion
In conclusion, this study of all patients with NSTEMI in a whole country over 20 years shows the gradual uptake of new evidence-based invasive and medical treatments and the simultaneously improved 1-year survival and reduction in MI, heart failure, and stroke and with reduction in event rates that also were sustained and further expanded during the entire 20 years follow-up period. The continuous monitoring of patient characteristics, co-morbidities, treatments, and outcomes in the patient population of a whole country also allowed the conclusion that the gradual implementation of the new evidence-based early invasive and medical treatment strategies was the main reason for the substantial reduction both in mortality and morbidity observed in patients with NSTEMI over the last 20 years. Therefore, a continued and increased use of the currently guideline recommended invasive and non-invasive treatment strategies can be expected to improve outcomes and be of substantial benefit to the society in all countries.
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